Insider Buying: Immunome (NASDAQ:IMNM) Director Acquires $204,225.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime acquired 10,500 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was acquired at an average cost of $19.45 per share, for a total transaction of $204,225.00. Following the completion of the purchase, the director owned 43,415 shares in the company, valued at $844,421.75. The trade was a 31.90% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

• On Friday, May 15th, Jean Jacques Bienaime acquired 5,000 shares of Immunome stock. The stock was acquired at an average cost of $20.70 per share, for a total transaction of $103,500.00.
• On Wednesday, March 11th, Jean Jacques Bienaime acquired 1,000 shares of Immunome stock. The stock was acquired at an average cost of $21.55 per share, for a total transaction of $21,550.00.

Immunome Trading Up 1.1%

Shares of NASDAQ IMNM opened at $18.36 on Friday. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -7.71 and a beta of 2.04. Immunome, Inc. has a 52 week low of $7.96 and a 52 week high of $27.65. The company’s 50-day moving average price is $21.85 and its 200 day moving average price is $21.71.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. As a group, research analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Leerink Partners lowered their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. Truist Financial raised their price target on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Stephens decreased their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. Finally, Craig Hallum raised their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.17.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of IMNM. Assetmark Inc. purchased a new position in shares of Immunome during the 3rd quarter worth about $39,000. KBC Group NV purchased a new position in shares of Immunome during the 1st quarter worth about $60,000. BNP Paribas Financial Markets lifted its holdings in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares during the period. Strs Ohio purchased a new position in shares of Immunome during the 4th quarter worth about $64,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares during the period. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.